Experienced in Dermatomyositis

Dr. Shaikh A. Ali

Rheumatology
455 School St, N27, 
Tomball, TX 
Accepting New Patients
Offers Telehealth
Experienced in Dermatomyositis
455 School St, N27, 
Tomball, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shaikh Ali is a Rheumatologist in Tomball, Texas. Dr. Ali is rated as an Experienced provider by MediFind in the treatment of Dermatomyositis. His top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Postmenopausal Osteoporosis. Dr. Ali is currently accepting new patients.

His clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in TX
Hospital Affiliations
Hca Houston Healthcare Tomball
Languages Spoken
English
Spanish
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sunshine Health
  • EPO
  • HMO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

455 School St, N27, Tomball, TX 77375

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Elite in Dermatomyositis
Dr. Eleni Tiniakou
Rheumatology
Elite in Dermatomyositis
Dr. Eleni Tiniakou
Rheumatology

UT Physicians

6410 Fannin St, Suite 604, 
Houston, TX 
 (28.9 miles away)
832-325-7070
Languages Spoken:
English, German, Greek
See accepted insurances
Accepting New Patients

Eleni Tiniakou is a Rheumatologist in Houston, Texas. Dr. Tiniakou is rated as a Distinguished provider by MediFind in the treatment of Dermatomyositis. Her top areas of expertise are Dermatomyositis, Myositis, Polymyositis, and Necrotizing Myopathy (NM). Dr. Tiniakou is currently accepting new patients.

Advanced in Dermatomyositis
Dr. Maryam Khawari
Rheumatology
Advanced in Dermatomyositis
Dr. Maryam Khawari
Rheumatology
777 S Fry Rd, Suite 208, 
Katy, TX 
 (22.3 miles away)
281-652-5943
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Maryam Khawari is a Rheumatologist in Katy, Texas. Dr. Khawari is rated as an Advanced provider by MediFind in the treatment of Dermatomyositis. Her top areas of expertise are Dermatomyositis, Rheumatoid Arthritis (RA), Mixed Connective Tissue Disease, and MASS Phenotype. Dr. Khawari is currently accepting new patients.

Advanced in Dermatomyositis
Dr. Namieta M. Janssen
Rheumatology
Advanced in Dermatomyositis
Dr. Namieta M. Janssen
Rheumatology

Namieta M. Janssen MD PLLC

1327 Lake Pointe Pkwy, Suite 535, 
Sugar Land, TX 
 (33.3 miles away)
832-500-5002
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Namieta Janssen is a Rheumatologist in Sugar Land, Texas. Dr. Janssen is rated as an Advanced provider by MediFind in the treatment of Dermatomyositis. Her top areas of expertise are Dermatomyositis, Rheumatoid Arthritis (RA), Psoriatic Arthritis, and Psoriasis. Dr. Janssen is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ali's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile